Trials / Completed
CompletedNCT04061395
Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study.
Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study. The HiGUS-trial
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- University Medical Center Groningen · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter open-label mode of action study. Twenty patients with moderate to severe hidradenitis suppurativa will be treated with guselkumab 200 mg Q4W subcutaneously. Main objectie is to investigate changes in inflammatory pathways induced by IL-23p19 blockade with guselkumab, in HS lesional skin. The total duration of the treatment period per subject is 16 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Guselkumab | See study arm description. |
Timeline
- Start date
- 2019-10-01
- Primary completion
- 2021-12-30
- Completion
- 2022-04-01
- First posted
- 2019-08-19
- Last updated
- 2024-04-05
Locations
2 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT04061395. Inclusion in this directory is not an endorsement.